Abstract
Effective immunotherapy, whether by checkpoint blockade or adoptive cell therapy, is limited in most patients by a key barrier: the immunosuppressive tumor microenvironment. Suppression of tumor-specific T cells is orchestrated by the activity of a variety of stromal myeloid and lymphoid cells. These often display inducible suppressive mechanisms that are triggered by the same anti-tumor inflammatory response that the immunotherapy intends to create. Therefore, a more comprehensive understanding of how the immunosuppressive milieu develops and persists is critical in order to harness the full power of immunotherapy of cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1-6 |
Number of pages | 6 |
Journal | Current Opinion in Immunology |
Volume | 39 |
DOIs | |
State | Published - Apr 1 2016 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology